Avalide Tablet, Film Coated
Product Images NDC 0024-5856

Product Visual Gallery

This gallery contains 10 technical images submitted to the FDA as part of the official labeling for Avalide (NDC 0024-5856). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Sanofi-aventis U.s. Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Figure 1a (0d91895e C869 4b33 9b83 D55c1ad6317e 01)

A line graph showing the relationship between baseline systolic blood pressure (SBP) in mmHg on the x-axis and the percentage of patients with SBP under 140 mmHg on the y-axis. The graph includes multiple lines representing different studies and treatment groups involving Avalide (irbesartan and hydrochlorothiazide).*

FDA Label Image

Figure 1b (0d91895e C869 4b33 9b83 D55c1ad6317e 02)

A line graph showing the percentage of subjects with systolic blood pressure (SBP) less than 130 mmHg plotted against baseline SBP in mmHg. The graph compares results from different studies labeled as Av. Study V, Irb. Study V, HCTZ Study V, Av. Study VI, and Irb. Study VI, with distinct line styles and colors representing each study group.*

FDA Label Image

Figure 2a (0d91895e C869 4b33 9b83 D55c1ad6317e 03)

A line graph depicting the relationship between baseline diastolic blood pressure (DBP) in mmHg (x-axis) and the percentage of recordings with DBP below 90 mmHg (y-axis), comparing results from different studies involving irbesartan (Irb) and hydrochlorothiazide (HCTZ). Multiple lines represent average and individual study outcomes for these treatments.*

FDA Label Image

Figure 2b (0d91895e C869 4b33 9b83 D55c1ad6317e 04)

A line graph comparing percentage DBP (diastolic blood pressure) reduction over baseline DBP (mmHg) across different studies labeled as Study V and Study VI with lines for Averaged Study V, Irbesartan Study V, Hydrochlorothiazide (HCTZ) Study V, Averaged Study VI, and Irbesartan Study VI. The x-axis represents baseline DBP values ranging approximately from 90 to 130 mmHg, and the y-axis shows percentage DBP reduction up to 100%. The graph depicts trends of DBP reduction with varying baseline DBP in different study groups.*

FDA Label Image

Chemical Structure (0d91895e C869 4b33 9b83 D55c1ad6317e 05)

Chemical structure of irbesartan, one of the active ingredients in Avalide tablets (irbesartan and hydrochlorothiazide). The diagram shows the molecular framework of the irbesartan compound.*

FDA Label Image

Chemical Structure (0d91895e C869 4b33 9b83 D55c1ad6317e 06)

Chemical structure diagram depicting the molecular formula of the active ingredient irbesartan from the Avalide medication, showing its detailed atomic connections and functional groups.*

FDA Label Image

Figure 3 (0d91895e C869 4b33 9b83 D55c1ad6317e 07)

A chart showing the relationship between irbesartan dose (mg/day) on the x-axis and mmHg measurements on the y-axis, depicting placebo-subtracted reduction in trough SeSBP. The graph includes data points and a curve representing the integrated analysis of dose response up to 900 mg/day.*

FDA Label Image

Figure 4 (0d91895e C869 4b33 9b83 D55c1ad6317e 08)

A scatter plot with a fitted curve showing the placebo-subtracted reduction in trough SeDBP (mmHg) on the y-axis versus Irbesartan dose (mg/day) on the x-axis, ranging from 0 to 900 mg/day. Data points cluster at lower doses with diminishing returns at higher doses.*

FDA Label Image

Principal Display Panel (0d91895e C869 4b33 9b83 D55c1ad6317e 09)

Avalide 150/12.5 mg film-coated tablets label showing the combination of irbesartan and hydrochlorothiazide. The label states the tablet count as 30 tablets, indicates prescription use, and lists storage instructions. The labeler is Sanofi-Aventis U.S. LLC. The label includes a barcode and various product identification numbers.*

FDA Label Image

Principal Display Panel (0d91895e C869 4b33 9b83 D55c1ad6317e 10)

Avalide 300/12.5 mg film-coated tablets label showing the product name and active ingredients irbesartan and hydrochlorothiazide. The label includes strength (300 mg irbesartan/12.5 mg hydrochlorothiazide), quantity of 30 tablets, the NDC 0024-5856-30, and the labeler Sanofi-Aventis U.S. LLC. Storage and disposition instructions are visible along with a barcode and serialization details.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.